 |
2023 News Releases
Mar. 14, 2023 - Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
Read
Mar. 3, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Mar. 2, 2023 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
Feb. 28, 2023 - Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
Read
Feb. 16, 2023 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
Read
Feb. 1, 2023 - Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Read
Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
Read
Jan. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
Jan. 9, 2023 - Puma Biotechnology Releases Updated Corporate Presentation
Read
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
